Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Axonics Modulation Technologies, Inc is a medical devices business based in the US. Axonics Modulation Technologies shares (AXNX) are listed on the NASDAQ and all prices are listed in US Dollars. Axonics Modulation Technologies employs 302 staff and has a trailing 12-month revenue of around USD$86.7 million.
|Latest market close||USD$45.8|
|52-week range||USD$15.25 - USD$52.1|
|50-day moving average||USD$45.3785|
|200-day moving average||USD$43.4188|
|Wall St. target price||USD$61|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.529|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-12.75%|
|1 month (2020-12-17)||3.71%|
|3 months (2020-10-15)||-4.60%|
|6 months (2020-07-15)||14.99%|
|1 year (2020-01-15)||50.46%|
|2 years (2019-01-15)||205.54%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$86.7 million|
|Gross profit TTM||USD$7.3 million|
|Return on assets TTM||-17.3%|
|Return on equity TTM||-34.35%|
|Market capitalisation||USD$1.9 billion|
TTM: trailing 12 months
There are currently 5.4 million Axonics Modulation Technologies shares held short by investors – that's known as Axonics Modulation Technologies's "short interest". This figure is 4.4% up from 5.2 million last month.
There are a few different ways that this level of interest in shorting Axonics Modulation Technologies shares can be evaluated.
Axonics Modulation Technologies's "short interest ratio" (SIR) is the quantity of Axonics Modulation Technologies shares currently shorted divided by the average quantity of Axonics Modulation Technologies shares traded daily (recently around 428689.21259843). Axonics Modulation Technologies's SIR currently stands at 12.7. In other words for every 100,000 Axonics Modulation Technologies shares traded daily on the market, roughly 12700 shares are currently held short.
However Axonics Modulation Technologies's short interest can also be evaluated against the total number of Axonics Modulation Technologies shares, or, against the total number of tradable Axonics Modulation Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axonics Modulation Technologies's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Axonics Modulation Technologies shares in existence, roughly 150 shares are currently held short) or 0.1838% of the tradable shares (for every 100,000 tradable Axonics Modulation Technologies shares, roughly 184 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Axonics Modulation Technologies.
Find out more about how you can short Axonics Modulation Technologies stock.
We're not expecting Axonics Modulation Technologies to pay a dividend over the next 12 months.
Over the last 12 months, Axonics Modulation Technologies's shares have ranged in value from as little as $15.25 up to $52.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axonics Modulation Technologies's is -0.0014. This would suggest that Axonics Modulation Technologies's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Axonics Modulation Technologies has bucked the trend.
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.